IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Summary

This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma

Timeline

Start

2024-12-06

Primary completion

2027-12-07

Completion

2027-12-07

Drugs

Indications